But at the very least, the last year has complicated the popular narrative that drug manufacturers and businessmen are selfish profit-taking parasites, hoarding wealth at the expense of the sick. Faced with the challenge of the novel coronavirus, big pharmaceutical companies didn’t just beat their record for developing a new vaccine. They utterly demolished it. Multiple vaccines have been created and tested in under a year. The previous record was set in the 1960s by the mumps vaccine, which took five times longer.
The fact that there were numerous firms racing toward many different vaccines wasn’t wasteful; it was crucial redundancy on a difficult high-stakes problem where time was of the essence. And one reason so many were able to spin up COVID response efforts quickly is that they were already sitting on giant piles of cash, enormous, expensive labs, and offices full of well-paid scientists, engineers, and strategists.
This is how pharmaceutical firms work: They laboriously develop and test new drugs, then sell them at a profit. The money they make is reinvested into more research—the leading firms plow about a quarter of their total sales into R&D—and, crucially, profits attract more capital.
In 2019, the top 10 pharmaceutical companies invested over $82 billion in research and development, according to the drug data firm Evaluate. If you include the whole industry, that number is closer to $150 billion. Compare that to the total budget of the National Institutes of Health, which was $39 billion the same year. When the threat posed by COVID-19 became clear, Pfizer, Gilead, Moderna, and others dropped ongoing research projects and diverted billions to solving the puzzle of the pandemic.
This story is from the February 2021 edition of Reason magazine.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the February 2021 edition of Reason magazine.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
THE LIBERTARIAN MIND OF DAVID BOAZ
Threats to freedom, Trump vs. Biden, and the wins libertarians can’t seem to acknowledge
DARE TO Fail
THERE’S NO SUCH thing as a universal millennial experience, but DARE comes close.
CULTURE WARRIOR IN CHIEF
THE MODERN PRESIDENCY IS A DIVIDER, NOT A UNITER. IT HAS BECOME FAR TOO POWERFUL TO BE ANYTHING ELSE.
Progress, Rediscovered
A NEW MOVEMENT PROMOTING SCIENTIFIC, TECHNOLOGICAL, AND ECONOMIC SOLUTIONS TO HUMANITY’S PROBLEMS EMERGES.
'Smoking Opium Is Not Our Vice'
AMERICA’S FIRST DRUG WAR WAS DRIVEN BY XENOPHOBIA AGAINST CHINESE MIGRANTS.
HOW CAPITALISM BEAT COMMUNISM IN VIETNAM
IT ONLY TOOK A GENERATION TO GO FROM RATION CARDS TO EXPORTING ELECTRONICS.
50 Years of D&D: You Can't Copyright Fun
THIS YEAR MARKS the 50th anniversary of the original edition of Dungeons & Dragons (D&D), the granddaddy of tabletop role-playing games and one of the urtexts of nerd culture.
The Pupil Panopticon
BIG BROTHER—and Parent, and Teacher— are watching.
Congress Could Swipe Your Credit Reward Points
A PLOT TO kill credit card reward points has bipartisan buy-in, with lawmakers framing the effort as an attempt to curb stillstubborn inflation.
Regulators Killed a Lifeline for Roombas
IN JANUARY 2024, Amazon terminated its agreement to acquire iRobot, the company that manufactures the Roomba robot vacuum.